InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture and commercialization of rare cannabinoids. This is an all-stock transaction in which InMed will issue 1.78m shares to BayMedica’s equity and convertible debt holders. At the current stock price, this values BayMedica at approximately US$4m. Following the closure of the transaction, the combined company will have expertise in both yeast and bact ....
20 Sep 2021
InMed Pharmaceuticals - Acquiring BayMedica
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
InMed Pharmaceuticals - Acquiring BayMedica
- Published:
20 Sep 2021 -
Author:
Maxim Jacobs -
Pages:
6
InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture and commercialization of rare cannabinoids. This is an all-stock transaction in which InMed will issue 1.78m shares to BayMedica’s equity and convertible debt holders. At the current stock price, this values BayMedica at approximately US$4m. Following the closure of the transaction, the combined company will have expertise in both yeast and bact ....